Recombinant Human Erythropoietin/EPO Protein (HEK293)，hFc

Erythropoietin (EPO) is a glycoprotein hormone primarily produced in the kidneys that stimulates erythropoiesis, the production of red blood cells. Its significant role in regulating erythrocyte formation makes it a critical factor in managing conditions associated with anemia, particularly in patients with chronic kidney disease, cancer, and those undergoing chemotherapy. The recombinant form of EPO, known as recombinant human erythropoietin (rHuEPO), was developed in the late 20th century through recombinant DNA technology and has transformed therapeutic approaches in hematology. Research on rHuEPO has expanded beyond its primary indication for anemia, investigating its potential neuroprotective effects in various neurological conditions and its application in enhancing exercise performance, albeit with ethical implications in sports. Furthermore, ongoing studies focus on optimizing the pharmacokinetics, efficacy, and safety profile of different EPO formulations, including pegylated versions which provide longer-lasting effects. The development of biosimilars also reflects the growing interest and market potential for EPO variants. Overall, the extensive research into EPO and its recombinant forms has underscored their importance in both clinical practice and biomedical research, highlighting the evolving landscape of therapeutic interventions targeting erythropoiesis.